Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2179-2182

  Burstein, Harold J ^a   Piccart Gebhart, Martine J ^b   Perez, Edith A ^c   Hortobagyi, Gabriel N ^d   Wolmark, Norman ^e   Albain, Kathy S ^f   Norton, Larry ^g   Winer, Eric P ^a   Hudis, Clifford A ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JULES BORDET INSTITUTE   (Belgium)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER RECURRENCE; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2;

EID: 84864018416     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.0695     Document Type: Note

References (19)

1. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
2. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
3. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
4. Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
5. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010
6. Perez EA, Suman VJ, Davidson NE, et al: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497, 2011
7. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
8. Bergstrom KA, Wang Z, Aksamit I, et al: Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices. Presented at the 2010 American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, October 1-3, 2010
9. Bayraktar S, Gonzalez-Angulo AM, Lei X, et al: Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline- based regimens for HER2-positive breast cancer. Cancer 118:2385-2393, 2012
10. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008 (Pubitemid 351767337)
11. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
12. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004 (Pubitemid 38771819)
13. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:146-156, 2011
14. Citron ML, Berry DA, Cirincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:431-439, 2003
15. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
16. Press M, Sauter G, Boyce M, et al: Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859-867, 2011
17. Gianni L, Norton L, Wolmark N, et al: Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27:4798-4808, 2009
18. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
19. Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 17:3490-3499, 2011